Aachen, Germany & Morristown, N.J. – Grünenthal, a global leader in pain management and related diseases, announced today that its U.S. subsidiary, Averitas Pharma, Inc., has completed recruitment for the Phase III clinical trial AV001. The trial aims to evaluate the efficacy, safety, and tolerability of QUTENZA® (capsaicin) 8% topical system in post-surgical neuropathic pain (PSNP). If successful…
